Symbiomix Therapeutics racks up $41 mln
Newark, New Jersey-based Symbiomix Therapeutics, which develops medicines for serious women's health infections, has received the final tranche of its $41 million Series A round. The investors included OrbiMed, Fidelity BioSciences and HBM Partners.
6 May 2015•5 mins read
